Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Nasr, M. Guillemin, Omar Ferhi, H. Soilihi, L. Pérès, C. Berthier, P. Rousselot, M. Robledo-Sarmiento, V. Lallemand-Breitenbach, B. Gourmel, D. Vitoux, P. Pandolfi, C. Rochette-Egly, Jun Zhu, H. Thé (2008)
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradationNature Medicine, 14
(2004)
Phase III study of all - trans retinoic acid in previously untreated patients 61 years or older with acute myeloid
Xuefeng He, Qinrong Wang, Jian-nong Cen, Huiying Qiu, A. Sun, Su-Ning Chen, Depei Wu (2016)
Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CRBone Marrow Transplantation, 51
T. Schenk, W. Chen, S. Göllner, L. Howell, Liqing Jin, K. Hebestreit, H. Klein, A. Popescu, A. Burnett, K. Mills, R. Casero, L. Marton, P. Woster, M. Minden, M. Dugas, Jean Wang, J. Dick, C. Müller-Tidow, K. Petrie, A. Zelent (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemiaNature Medicine, 18
H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. Appelbaum, T. Büchner, H. Dombret, B. Ebert, P. Fenaux, R. Larson, R. Levine, F. Lo‐Coco, T. Naoe, D. Niederwieser, G. Ossenkoppele, M. Sanz, J. Sierra, M. Tallman, H. Tien, A. Wei, B. Löwenberg, C. Bloomfield (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood, 129 4
Han Verhagen, Marjon Smit, A. Rutten, F. Denkers, P. Poddighe, P. Merle, G. Ossenkoppele, L. Smit (2016)
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.Blood, 127 4
Retinoic acid-induced CD38 expression in HL-60
S. Lugthart, S. Gröschel, H. Beverloo, S. Kayser, P. Valk, S. Zelderen-Bhola, Gert Ossenkoppele, E. Vellenga, E. Ruiter, U. Schanz, G. Verhoef, P. Vandenberghe, A. Ferrant, C. Köhne, M. Pfreundschuh, H. Horst, E. Koller, M. Lilienfeld-Toal, M. Bentz, A. Ganser, B. Schlegelberger, M. Jotterand, J. Krauter, T. Pabst, M. Theobald, R. Schlenk, R. Delwel, K. Döhner, B. Löwenberg, H. Döhner (2010)
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 24
Birgit Steinmetz, H. Hackl, Eva Slabáková, I. Schwarzinger, Monika Smějová, A. Spittler, Itziar Arbesú, M. Shehata, K. Souček, R. Wieser (2014)
The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acidCell Cycle, 13
ZF Xi, M. Russell, S. Woodward, F. Thompson, L. Wagner, R. Taetle (1997)
Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemiaLeukemia, 11
A. Hinai, P. Valk (2016)
Review: Aberrant EVI1 expression in acute myeloid leukaemiaBritish Journal of Haematology, 172
S. Goyama, G. Yamamoto, M. Shimabe, Tomohiko Sato, M. Ichikawa, S. Ogawa, S. Chiba, M. Kurokawa (2008)
Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.Cell stem cell, 3 2
(2016)
Aberrant EVI1 expression in acute myeloid leukaemia
(2002)
All-trans retinoic acid in combination with intermediatedose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial
(2018)
Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of non promyelocytic acute myeloid leukemiasCancer Res, 78
D. Milligan, K. Wheatley, T. Littlewood, J. Craig, A. Burnett (2006)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.Blood, 107 12
C. Chim, S. Wong, A. Pang, P. Chu, J. Lau, K. Wong, Y. Kwong (2005)
Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemiaLeukemia, 19
Li-na Wang, Yanlai Tang, Ying-Chuan Zhang, Zu-Han Zhang, Xiao-jian Liu, Zhi-yong Ke, Yu Li, Huiliu Tan, Li-Bin Huang, Xue-Qun Luo (2017)
Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathwaysLeukemia & Lymphoma, 58
A. Burnett, R. Hills, D. Milligan, A. Goldstone, A. Prentice, M. McMullin, A. Duncombe, B. Gibson, K. Wheatley (2010)
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
E. Estey, P. Thall, S. Pierce, J. Cortes, M. Beran, H. Kantarjian, M. Keating, M. Andreeff, E. Freireich (1999)
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.Blood, 93 8
N. Gils, Han Verhagen, L. Smit (2017)
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.Experimental hematology, 52
F. Lo‐Coco, G. Avvisati, M. Vignetti, C. Thiede, S. Orlando, S. Iacobelli, F. Ferrara, P. Fazi, L. Cicconi, E. Bona, G. Specchia, S. Sica, M. Divona, A. Levis, W. Fiedler, E. Cerqui, M. Breccia, G. Fioritoni, H. Salih, M. Cazzola, L. Melillo, A. Carella, C. Brandts, E. Morra, M. Lilienfeld-Toal, B. Hertenstein, M. Wattad, M. Lübbert, M. Hänel, N. Schmitz, H. Link, M. Kropp, A. Rambaldi, G. Nasa, M. Luppi, F. Ciceri, O. Finizio, A. Venditti, F. Fabbiano, K. Döhner, M. Sauer, A. Ganser, S. Amadori, F. Mandelli, H. Döhner, G. Ehninger, R. Schlenk, U. Platzbecker (2013)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.The New England journal of medicine, 369 2
R. Schlenk, M. Lübbert, A. Benner, Alexander Lamparter, J. Krauter, W. Herr, H. Martin, H. Salih, A. Kündgen, H. Horst, P. Brossart, K. Götze, D. Nachbaur, M. Wattad, C. Köhne, W. Fiedler, M. Bentz, G. Wulf, G. Held, B. Hertenstein, H. Salwender, V. Gaidzik, B. Schlegelberger, D. Weber, K. Döhner, A. Ganser, H. Döhner (2016)
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyAnnals of Hematology, 95
A. Plesa, C. Dumontet, Eve Mattei, Ines Tagoug, S. Hayette, P. Sujobert, I. Tigaud, M. Pagès, Y. Chelghoum, F. Baracco, Helene Labussierre, S. Ducastelle, E. Paubelle, F. Nicolini, M. Elhamri, L. Campos, C. Plesa, S. Morisset, G. Salles, Y. Bertrand, M. Michallet, X. Thomas (2017)
High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemiaWorld Journal of Stem Cells, 9
S. Lugthart, M. Figueroa, E. Bindels, L. Skrabanek, P. Valk, Yushan Li, S. Meyer, Claudia Erpelinck-Verschueren, J. Greally, B. Löwenberg, A. Melnick, R. Delwel (2011)
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.Blood, 117 1
R. Schlenk, S. Fröhling, F. Hartmann, J. Fischer, A. Glasmacher, F. Valle, W. Grimminger, K. Götze, C. Waterhouse, R. Schoch, H. Pralle, H. Mergenthaler, M. Hensel, E. Koller, H. Kirchen, J. Preiß, H. Salwender, H. Biedermann, S. Kremers, F. Griesinger, A. Benner, B. Addamo, K. Döhner, R. Haas, H. Döhner, for Ulm (2004)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemiaLeukemia, 18
L. Laricchia‐Robbio, R. Fazzina, Donglan Li, C. Rinaldi, K. Sinha, S. Chakraborty, G. Nucifora (2006)
Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow CellsMolecular and Cellular Biology, 26
Changhee Kang, C‐Yoon Kim, Hyuk Kim, Se-Pill Park, H. Chung (2018)
The Bromodomain Inhibitor JQ1 Enhances the Responses to All-trans Retinoic Acid in HL-60 and MV4-11 Leukemia CellsInternational Journal of Stem Cells, 11
(1990)
Alltrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia
Hayley Ma, S. Greenblatt, Courtney Shirley, A. Duffield, J. Bruner, Li Li, Bao Nguyen, Eric Jung, P. Aplan, G. Ghiaur, Richard Jones, D. Small (2016)
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Blood, 127 23
Julien Ablain, M. Leiva, L. Pérès, J. Fonsart, Élodie Anthony, H. Thé (2013)
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapiesThe Journal of Experimental Medicine, 210
A. Burnett, D. Milligan, A. Prentice, A. Goldstone, M. McMullin, R. Hills, K. Wheatley (2007)
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 109
Sahar Doorn-Khosrovani, Claudia Erpelinck, W. Putten, P. Valk, Sonja Luytgaarde, Ronald Hack, R. Slater, E. Smit, H. Beverloo, G. Verhoef, L. Verdonck, G. Ossenkoppele, P. Sonneveld, G. Greef, B. Löwenberg, R. Delwel (2003)
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.Blood, 101 3
A. Gentles, S. Plevritis, R. Majeti, Ash Alizadeh (2010)
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.JAMA, 304 24
Helena Boutzen, E. Saland, C. Larrue, F. Toni, L. Gales, F. Castelli, Mathilde Cathebas, Sonia Zaghdoudi, Lucille Stuani, T. Kaoma, Romain Riscal, Guangli Yang, P. Hirsch, M. David, Véronique Mas-Mansat, É. Delabesse, L. Vallar, F. Delhommeau, I. Jouanin, O. Ouerfelli, L. Cam, L. Linares, C. Junot, J. Portais, F. Vergez, C. Récher, J. Sarry (2016)
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemiaThe Journal of Experimental Medicine, 213
Nathaniel Buteyn, Kavin Fatehchand, R. Santhanam, Huiqing Fang, G. Dettorre, S. Gautam, Bonnie Harrington, Sally Henderson, Giovanna Merchand-Reyes, X. Mo, D. Benson, W. Carson, S. Vasu, J. Byrd, Jonathan Butchar, S. Tridandapani (2018)
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemiaInternational Immunology, 30
H. Baik, Mathias Boulanger, M. Hosseini, J. Kowalczyk, Sonia Zaghdoudi, Tamara Salem, J. Sarry, Y. Hicheri, G. Cartron, M. Piechaczyk, G. Bossis (2018)
Targeting the SUMO pathway primes all-trans-retinoic acid-induced differentiation of non promyelocytic Acute Myeloid LeukemiasbioRxiv
S. Gröschel, S. Lugthart, R. Schlenk, P. Valk, Karina Eiwen, Chantal Goudswaard, W. Putten, S. Kayser, L. Verdonck, M. Lübbert, G. Ossenkoppele, U. Germing, I. Schmidt-Wolf, B. Schlegelberger, J. Krauter, A. Ganser, H. Döhner, B. Löwenberg, K. Döhner, R. Delwel (2010)
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 12
I. Vázquez, M. Maicas, J. Cervera, X. Agirre, O. Marin-Bejar, N. Marcotegui, C. Vicente, I. Lahortiga, M. Gómez-Benito, C. Carranza, A. Valencia, S. Brunet, E. Lumbreras, F. Prósper, M. Gomez-Casares, J. Hernández-Rivas, M. Calasanz, M. Sanz, J. Sierra, M. Odero (2011)
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemiaHaematologica, 96
S. Castaigne, C. Chomienne, Danielson Mt, P. Ballerini, R. Berger, P. Fenaux, L. Degos (1990)
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.Blood, 76 9
Thomas Lamkin, V. Chin, Susi Varvayanis, James Smith, R. Sramkoski, J. Jacobberger, A. Yen (2006)
Retinoic acid‐induced CD38 expression in HL‐60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levelsJournal of Cellular Biochemistry, 97
(2017)
High frequency of CD34CD38/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
(2011)
Down - regulation of EVI 1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
(2018)
Antileukemic effects of all-trans retinoic acid in combination with daratumumab in acute myeloid leukemia
A. Belhabri, X. Thomas, E. Wattel, Y. Chelghoum, B. Anglaret, A. Vekhoff, O. Reman, H. Dombret, N. Dhedin, M. Michallet, D. Fiére, E. Archimbaud (2002)
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.The hematology journal : the official journal of the European Haematology Association, 3 1
M. Martelli, Ilaria Gionfriddo, Federica Mezzasoma, F. Milano, S. Pierangeli, Floriana Mulas, R. Pacini, A. Tabarrini, V. Pettirossi, R. Rossi, C. Vetro, L. Brunetti, P. Sportoletti, E. Tiacci, F. Raimondo, B. Falini (2015)
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.Blood, 125 22
Oncol Ther (2019) 7:121–130 https://doi.org/10.1007/s40487-019-0095-9 ORIGINAL RESEARCH Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 . . . . Etienne Paubelle Adriana Plesa Sandrine Hayette Mohamed Elhamri . . . Florence Zylbersztejn Olivier Hermine Gilles Salles Xavier Thomas Received: January 9, 2019 / Published online: May 22, 2019 The Author(s) 2019 addition of ATRA might be of benefit in the ABSTRACT treatment of patients with EVI1-positive AML. Introduction: EVI1 (MECOM)-positive acute Keywords: Acute myeloid leukemia; All-trans- myeloid leukemia (AML) cells have shown retinoic acid; EVI1; Leukemia stem cells; in vitro sensitivity to all-trans-retinoic acid MECOM (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods: In this pilot study, we investigated INTRODUCTION the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Acute myeloid leukemia (AML) is the predomi- Results: Seven of the 13 patients (53.8%) nant acute leukemia among adults, character- achieved complete remission (CR), and ized by an accumulation of malignant response can be combined with a decreased of immature myeloid precursors. It represents a the leukemia stem cell pool. heterogeneous group of diseases with different Conclusion: These primary results tend to responses to treatment, which can be
Oncology and Therapy – Springer Journals
Published: May 22, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.